Hua Li

Identification of CD40 as the target of artemisinin via targeted degradomics for ulcerative colitis.

Current drugs for ulcerative colitis often face challenges such as significant side effects, high costs, and tendency to induce drug resistance. Repurposing existing drugs is a promising approach that builds on their known safety and efficacy profiles. Artemisinin (Art), a first-line antimalarial agent, shows anti-infl...